Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 10/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | BRD1 | O95696 | 1/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543649 | 0.92 | PKM (0.60) | PKMMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL7538064 | 0.86 | EGFR (0.49) | PKMMEN1KMT2ASMN1; SMN2EGFR | |
| SCHEMBL7536067 | 0.85 | PKM (0.48) | PKMMEN1KMT2ASMN1; SMN2EGFR | |
| SCHEMBL7541882 | 0.82 | TP53 (0.59) | PKMMEN1KMT2AEGFRMAPT | |
| SCHEMBL7536414 | 0.79 | EGFR (0.57) | PKMMEN1KMT2ASMN1; SMN2EGFR | |
| SCHEMBL7537514 | 0.77 | EGFR (0.49) | PKMMEN1KMT2ASMN1; SMN2EGFR | |
| SCHEMBL7536037 | 0.76 | PKM (0.55) | PKMMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL16948357 | 0.71 | ALDH1A1 (0.73) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7541742 | 0.71 | PKM (0.60) | PKMMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL7543069 | 0.70 | PKM (0.44) | PKMMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | PDK1, PC, PDK2 | PKM 11/4885MEN1 4239/4885KMT2A 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.